BioCryst to Present New ORLADEYO (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharmaceuticals will present two abstracts featuring data on ORLADEYO (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2023 European Academy of Allergy and Clinical Immunology (EAACI) congress in Hamburg, Germany.
May 31, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioCryst Pharmaceuticals' presentation of new ORLADEYO data at the 2023 EAACI congress may generate interest in the company's stock.
The presentation of new data on ORLADEYO at the EAACI congress may generate interest in BioCryst Pharmaceuticals' stock as it showcases the company's progress in developing treatments for hereditary angioedema. Positive data could potentially lead to increased demand for the company's product, which may positively impact the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100